Company intelligence / Profile preview

Eli Radiopharma

Suzhou, China

Ownership: Private
Development stage: Other

Overview

Eli Radiopharma is an emerging biotechnology company focused on the development of next-generation radiopharmaceuticals for the diagnosis and treatment of cancer. The company leverages a proprietary discovery platform to design targeted ligands that deliver radioactive isotopes directly to tumor cells while minimizing off-target effects. Their primary focus is on targeting Fibroblast Activation Protein (FAP), a protein highly expressed in the stroma of various solid tumors. Eli Radiopharma aims to advance its lead candidates into clinical trials to address significant unmet needs in oncology.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Drug pipeline

6 assets

ELI-301

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Eli Radiopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eli Radiopharma.

Explore the full profile